Search

Copyright of Molecular Imaging & Radionuclide Therapy is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Molecular Imaging & Radionuclide Therapy is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Nuclear Medicine Seminars is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Nuclear Medicine Seminars is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Nuclear Medicine Seminars is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Nuclear Medicine Seminars is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Nuclear Medicine Seminars is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Nuclear Medicine Seminars is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Nuclear Medicine Seminars is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Aim: The aim of this study is to reevaluate the ultrasound (US) findings of incidental hypermetabolic thyroid nodules using EU-TIRADS criteria and correlate the outcome with histopathology. Method: Three thousand seven hundred ninety-three florodeoksiglukoz (FDG) positron emission tomography/computerized tomography (PET/ CT) images performed in our department between September 2017 and December 2018 were evaluated retrospectively. Three hundred and twentyeight subjects with focal increased FDG uptake in thyroid lesions were noted. The ones who had fine needle aspiration biopsy (FNAB) results were enrolled in the study. US findings of these lesions were reevaluated using EU-TIRADS criteria. Standardized uptake value (SUVmax) of each focal thyroid lesion and SUVmax ratio (SUVmax/thyroid background activity) were calculated. These findings were correlated with FNAB results and their relationship were evaluated retrospectively. Results: Fifty-six hypermetabolic thyroid nodules in 46 patients were examined. The FNAB results were: 7 malignant, 5 suspicious for malignancy, 31 benign and the remainings were non-diagnostic. The SUVmax and SUVmax ratio median values of 12 focal activities which were found as malignant and suspicious for malignancy were 14.08 and 7.94, respectively; SUVmax and SUVmax ratio median values of 31 focal activities which were found as benign were 7.1 and 4.33, respectively. SUVmax and SUVmax ratio values were greater in the malign group than the benign group (Mann-Whitney U test, p=0.002 and p=0.024, respectively). The cut-off value of SUVmax and SUVmax ratio discriminating benign and malignant lesions were calculated using ROC analysis and were detected as 10.35 (with 83% sensitivity and 78% spesificity, p=0.002) and 6.12 (with 66% sensitivity and 71% spesificity, p=0.007), respectively. Malignancy ratios in different EU-TIRADS groups are given at Table 1. Sensitivity, spesificity, positive predictive value, negative predictive value and accuracy ratios for malignancy of three groups SUVmax >10.35, SUVmax ratio >6.12 and EU-TIRADS 5 are given at Table 2. Conclusion: EU-TIRADS criteria can discriminate the lesions at high risk for malignancy from those at low risk among hypermetabolic thyroid nodules incidentally detected on FDG PET/CT. Additionally, using a predetermined cut-off value for SUVmax and SUVmax ratio could further enhance our interpretation in the differentiation of benign and malignant thyroid nodules. [ABSTRACT FROM AUTHOR]

Aim: To evaluate the prevalence and clinical significance of focal parotid lesions with increased fokal uptake identified on florodeoksiglukoz (FDG) positron emission tomography/ computerized tomography (PET/CT) in patients with non-parotid malignancies. Method: FDG PET/CT images of 9.566 subjects performed between January 2016 to December 2018 were evaluted retrospectively. The ones with incidental focal FDG uptake in parotid gland with no prior history of primary parotid malignancies were noted. Clinical data was evaluated and the ones with pathology of parotid lesion were enrolled in the study. Maximum standardized uptake value (SUVmax) on PET images, patient demographics, clinical features, and histopathological diagnosis were evaluated for each subject. Results: We detected 121 patients (18 female, 103 male) with incidental focal hypermetabolic parotid uptake on PET/CT. The prevalence of incidental focal hypermetabolic parotid uptake on PET/CT was 1.2% (121/9566). Twenty-two patients with incidental focal hypermetabolic parotid uptake had histopathological diagnosis. Malignancy was found in 1 (4.5%) of the patients, malignancy could not be excluded in 3 (13.6%) of the patients, benign pathology was deteted in 18 (81.8%) of the patients (8 Warthin tumors, 2 oncocytomas, 8 other benign pathologies). The SUVmax mean ± standard deviation (SD) was 17.5±11 for benign lesions. The SUVmax of a single malignant lesion was 7.5. The SUVmax mean ± SD was 25.7±13.8 for the remaining 3 lesions pathologically suspicious for malignancy. Conclusion: Focal increased FDG uptake on parotid is rarely noted on FDG PET/CT images. In our study, incidental focal hypermetabolic lesions in the parotid gland were more frequently seen in male. Eventhough the SUVmax values were high, many of these lesions were benign. There was no correlation between SUVmax value and malignancy in incidental parotid focal activity. Therefore focal increased FDG uptake on parotid may warrant further investigation to ensure accurate diagnosis. [ABSTRACT FROM AUTHOR]

Objective: Aim the aim of this study was to investigate semiquantitatively the diagnostic performance of Tc-99m hexamethypropylene amine oxime labeled white blood cell (Tc-99m HMPAO-WBC) scintigraphy in patients with suspected bone or soft tissue infections. Methods: Material and Method twenty one patients who applied to Nuclear Medicine Departmant (for suspected prosthesis infection, diabetic foot, bone infection, graft infection) were evaluated retrospectively. Tc-99m HMPAO WBC scintigraphy imaging were performed to all patients. Planar images were taken 1., 2., and 4. hours after injecting the labeled leukocytes. Evaluation of infection with Tc-99m HMPAO WBC scintigraphy was done semiquantitatively. Relative uptake was determined by setting the region of interest (ROI) of lesion area on the anterior view. Rectangular ROI was set on the against limb (nonlesion). The ratio of the average pixel count in the lesion (L) to that in the non-lesion (NL) (L/NL ratio) was calculated at 1., 2., and 4. hours images. Final diagnosis was based on histopathology, microbiologic assays, or clinical and imaging follow-up. Results: 0.55 and 1.55±0.74, 1.42±0.55, 1.40±0.55 in positive and control groups, respectively. Positive group revealed a statistically significant increase L/NL values in the data 3 hours images (p=0.002). However, no statistically significant was found between L/NL values in 3 hours imaging data in control group (p=0.223). All the data in the positive group found a statistically increased steadily. Furthermore, statistically significant difference was found between the positive and control group at 2., and 4. hours images (p=0.015, and p=0.006). ±0.43, 2.05±0.35, 1.90±SD) values were found to be 1.74±Results of the 21 patients, 11 were found to have infection (positive group), whereas 10 had normal (control group) pathologies on histopathology, microbiologic assays, or clinical and imaging follow-up. First, 2., and 4. hours L/NL (mean). Conclusion: Leukocyte scintigraphy has been described as a useful diagnostic tool in the diagnosis of suspicion of bone and soft tissue infection, fever of unknown origin and suspicion of acute appendicitis. Tc-99m HMPAO labeled WBC scintigraphy is a rapid and very accurate method for detecting those pathologies, and it is evaluated visually. Our results showed that WBC scintigraphy might be evaluated semiquantitatively and reliable used for diagnosis of suspected bone and soft tissue infection. [ABSTRACT FROM AUTHOR]